Allakos Inc To discuss Lirentelimab Phase 2 Results Transcript
Ladies and gentlemen, thank you for standing by, and welcome to learn Palomar Phase 2 chronic spontaneous urticaria and atopic dermatitis results. (Operator Instructions) I would now like to turn the conference over to Robert Alexander, Chief Executive Officer. Please go ahead.
Thank you, operator. I'd like to thank everybody for joining our call today. And before we get started. A reminder that we will be making forward looking statements. Please refer to our SEC filings for a description of our risk factors. Joining me today in the room are our CFO, Baird Radford; our Head of Research, Brad Youngblood; and our President, Adam Tomasi; our Chief Medical Officer, Craig Paterson; and our Head of IR and VP of Finance, Alex Schwartz. In terms of the agenda, we'll have Chris, I'll turn it over to Craig here momentarily to go through the top-line results of the AD. and C. issue study. Bob Baird will then go through the restructuring of the company. And then lastly, I'll give an update on our oh six program. Craig?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |